Drew Fromkin, Proteovant CEO

Blue­print part­ners up with a de­grad­er-fo­cused 'van­t' as part of pipeline-boost­ing cam­paign

Part of Vivek Ra­maswamy and Matt Gline’s ex­pan­sive uni­verse of “vants,” the lit­tle-known de­grad­er play Pro­teo­vant has silent­ly been chip­ping away for more than a year. Now, Blue­print Med­i­cines will take a bet on that biotech and its AI-fo­cused sis­ter firm.

Blue­print will pay $20 mil­lion up­front and a po­ten­tial $632 mil­lion in ad­di­tion­al down­stream mile­stones for two pro­tein de­grad­er pro­grams from Pro­teo­vant with the op­tion to add two more pro­grams to the slate, the part­ners said Mon­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.